Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Aug 12
Materials: Storing energy in bricksNature Communications
-
Aug 11
Planetary science: Dawn’s close-up look at CeresNature Astronomy
-
Jul 30
Astrophysics: Finding the best view of the sky at nightNature
-
Jul 14
Bioengineering: Restoring damaged human lungs via cross-circulation to a pigNature Medicine
-
Jul 10
Engineering: Reducing noise transmitted through an open windowScientific Reports
-
Jul 9
Physics: The rise of the robotic researcherNature
